
Transplantation-associated thrombotic microangiopathy: risk factors and treatment outcome
Liu Jia, Zhu Lidan, Gao Shichun, Liu Huanfeng, Wang Lu, Zhang Cheng, Gao Li, Zhang Xi, Kong Peiyan, Gao Lei
Transplantation-associated thrombotic microangiopathy: risk factors and treatment outcome
Objective To investigate the effect of the clinical features,high-risk factors,and treatment regimens of transplantation-associated thrombotic microangiopathy(TA-TMA) on the early diagnosis and treatment outcome of TA-TMA. Methods A total of 40 patients with TA-TMA who were diagnosed in Hematology Medical Center,The Second Affiliated Hospital of Army Medical University,from January 2019 to June 2023 were enrolled as subjects,and 120 patients who did not experience TA-TMA after allogeneic hematopoietic stem cell transplantation during the same period of time were also enrolled. A retrospective analysis was performed for the clinical features,high-risk factors,treatment response,and survival status of TA-TMA patients. Results The binary logistic regression analysis showed that haploidentical transplantation,cytomegalovirus infection,acute graft-versus-host disease,and increased concentrations of calcium regulatory inhibitors were high-risk factors for TA-TMA(P<0.05). According to the treatment regimen,40 patients with TA-TMA were divided into regimen 1 group with 26 patients(with the treatment regimen of plasma exchange) and regimen 2 group with 14 patients(without the treatment regimen of plasma exchange). The results showed the survival of 8 patients in the regimen 1 group(30.8%) and 2 patients in the regimen 2 group(14.3%),and there was no significant difference in treatment outcome between the two groups(P>0.05). Conclusion Haploidentical hematopoietic stem cell transplantation,cytomegalovirus infection,and acute graft-versus-host disease are high-risk factors for TA-TMA. The results of this study show no significant difference in treatment efficacy between the treatment regimens with or without plasma exchange. It is recommended to select treatment regimens according to the patient’s conditions and TA-TMA treatment guidelines,and it is urgent to further explore better treatment regimens to improve the prognosis and survival rate of TA-TMA patients.
hematopoietic stem cell transplantation / transplanta-tion-associated thrombotic microangiopathy / risk factors / treatment outcome
1 |
韩 悦. 我如何治疗移植相关性血栓性微血管病[J]. 中华血液学杂志,2020,41(4):272-275.
|
2 |
中华医学会血液学分会造血干细胞应用学组. 造血干细胞移植相关血栓性微血管病诊断和治疗中国专家共识(2021年版)[J]. 中华血液学杂志,2021,42(3):177-184.
Hematopoietic stem cell Application Group,Hematology Society,Chinese Medical Association. Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy(2021)[J]. Chin J Hematol,2021,42(3):177-184.
|
3 |
|
4 |
|
5 |
|
6 |
|
7 |
|
8 |
莫晓冬,许兰平,刘代红,等. 急性移植物抗宿主病患者发生移植相关血栓性微血管病的危险因素及预后分析[J]. 中华内科杂志,2013,52(2):156-160.
|
9 |
|
10 |
|
11 |
|
12 |
|
13 |
|
14 |
徐一帆,魏 岩,郭佳媛,等. 基于不同预后风险模型对移植相关血栓性微血管病的疗效及预后分析[J]. 中国实验血液学杂志,2023,31(5):1501-1508.
|
15 |
陈 峰,吴德沛. 造血干细胞移植相关的血栓性微血管病的诊断和治疗[J]. 中国实用内科杂志,2023,43(6):453-456.
|
16 |
|
17 |
|
18 |
|
/
〈 |
|
〉 |